TEKCAPITAL PLC

Regulatory Filings • Mar 3, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4031Y

Tekcapital plc

03 March 2017

3 March 2017

Tekcapital plc

("Tekcapital" or the "Company")

BELLUSCURA LTD LAUNCHES PASSPORT® DISPOSABLE TROCAR IN USA

Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched Passport® in the United States. 

Passport is a disposable trocar used in laparoscopic, or 'keyhole' surgery, and features the patented SmartTip™ technology, designed to be compatible with the Da Vinci®1 S and Si robotic surgical systems.  Passport, with its unique seal, is used as the access point for the endoscope camera which allows the surgeon to visualise the procedure site.  The SmartTip controls the cutting blade to prevent accidental deployment inside the patient and potential tissue damage.

It is estimated that more than 7.5 million laparoscopic procedures are performed annually2, with 2.8 million being performed in the US alone.  Laparoscopic procedures continue to replace more invasive surgery because of the faster recovery, lower surgical headcount requirement and better training.3

Please click here for picture of Passport®

http://www.rns-pdf.londonstockexchange.com/rns/4031Y_-2017-3-2.pdf

Bob Rauker, Belluscura's CEO said: "The launch of this Passport trocar provides Belluscura with a presence in the surgical device field. Passport is the first of a family of trocars and cannulae that Belluscura will seek to launch over the coming years.  Together, these will form a range of products to support surgeons in an array of specialties."

About Belluscura:

Belluscura Limited is a global medical device company founded in Oxford, England.  Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines.  Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com.

Tekcapital owns approximately 65% of the share capital of Belluscura.

For further information, please contact:

Tekcapital Plc
Clifford M. Gross, Ph.D.	info@tekcapital.com
Allenby Capital Limited (Nominated Adviser & Joint Broker)	+44 (0) 20 3328 5656
Jeremy Porter / Alex Brearley
Dowgate Capital Stockbrokers (Joint Broker)	+44 (0) 1293 517744
David Poutney / James Serjeant
Walbrook PR Ltd	+44 (0) 20 7933 8780
Paul Cornelius / Helen Cresswell / Sam Allen	tekcapital@walbrookpr.com

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

LEI: 213800GOJTOV19FIFZ85 Note 1: Da Vinci® is a registered trademark of Intuitive Surgical, Inc. Note 2: https://www.quora.com/On-average-how-many-laparoscopic-surgeries-are-performed-in-a-year-worldwide Note 3: http://www.transenterix.com/assets/TransEnterix-JPM-2016-PDF-No-Video-    2-MB.pdf

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASSWFMEFWSEID